Pelthos Therapeutics Inc.

PTHS ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item Jun 2024 Mar 2024 Dec 2023 Sep 2023 Jun 2023 Mar 2023
Operating Activities
Net Income $-1.8M $-2.6M $-4.0M $-1.4M $-953.3K $-966.6K
Depreciation & Amortization
Depreciation
Amortization
Stock-Based Compensation $459.0K $292.6K $791.2K $342.4K $327.3K $272.2K
Net Cash from Operating Activities $-3.0M $-2.0M $-356.8K $-257.2K $-193.6K $-173.4K
Investing Activities
Capital Expenditures
Business Acquisitions
Net Cash from Investing Activities
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $1.6M $5.7M $430.4K $198.1K $226.9K $166.9K
Net Change in Cash
Free Cash Flow
← Newer Page 2 of 2 Older →